This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2025-07-23), BeOne Medicines's share price is $294.83. BeOne Medicines's Median PS Value is $0.00. Therefore, BeOne Medicines's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for BeOne Medicines's Median PS Value or its related term are showing as below:
ONC's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.71 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
BeOne Medicines Median PS Value Historical Data
The historical data trend for BeOne Medicines's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BeOne Medicines's Median PS Value
For the Biotechnology subindustry, BeOne Medicines's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
BeOne Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $38.921.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (NAS:ONC) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
BeOne Medicines's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
294.83
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines Median PS Value Related Terms
Thank you for viewing the detailed overview of BeOne Medicines's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONC has been successfully added to your 